Morgan Stanley initiated coverage of ResMed with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | Overweight | Analyst | |
| 12/16/2025 | $275.00 | Outperform → Neutral | Robert W. Baird |
| 9/18/2025 | $330.00 | Buy | Citigroup |
| 9/2/2025 | Hold → Outperform | CLSA | |
| 7/16/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 7/15/2025 | $294.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/19/2025 | $280.00 | Overweight | Morgan Stanley |
| 3/19/2025 | Overweight | Morgan Stanley |
SD - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders. The acquisition expands Resmed's clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact fo
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days. About ResmedResmed (
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
3 - RESMED INC (0000943819) (Issuer)
Analyst initiated coverage of ResMed with a rating of Overweight
Robert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00
Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%GAAP income from operations increased 17%; non-GAAP income from operations up 18%GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2026.
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST Please note, Resmed does not use outside phone lines t
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor. "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr